​

Palvella Therapeutics Ownership | Who Owns Palvella Therapeutics?

OverviewForecastFinancialsChart

Palvella Therapeutics Ownership Summary

Palvella Therapeutics is owned by 116.83% institutional investors, 11.65% insiders. Suvretta capital management is the largest institutional shareholder, holding 10.25% of PVLA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.53% of its assets in Palvella Therapeutics shares.

PVLA Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockPalvella Therapeutics116.83%11.65%-28.48%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Suvretta capital management1.15M10.25%$143.78M
First light asset management980.76K8.72%$122.25M
Bvf inc/il960.99K8.54%$119.79M
Frazier life sciences management882.40K7.84%$109.99M
Blackrock funding, inc. /de686.85K6.10%$85.62M
Jennison associates640.61K5.69%$79.85M
Vanguard group560.62K5.07%$58.68M
State street459.00K4.08%$57.21M
Federated hermes433.01K3.85%$53.98M
Price t rowe associates inc /md/402.56K3.58%$50.18M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
First light asset management980.76K10.96%$122.25M
Clio asset management90.76K9.48%$11.31M
Bvf inc/il960.99K3.82%$119.79M
Suvretta capital management1.15M3.67%$143.78M
Frazier life sciences management882.40K2.83%$109.99M
First turn management148.09K2.06%$18.46M
Avidity partners management lp70.00K2.03%$8.98M
Bioimpact capital206.40K1.99%$25.73M
Apis capital advisors89.00K1.71%$11.09M
Lisanti capital growth41.45K1.30%$5.17M

Top Buyers

HolderShares% AssetsChange
Price t rowe associates inc /md/402.56K0.01%398.47K
Frontier capital management374.04K0.48%374.04K
First light asset management980.76K10.96%271.62K
Suvretta capital management1.15M3.67%261.10K
Jennison associates640.61K0.05%253.13K

Top Sellers

HolderShares% AssetsChange
Summit partners public asset management---389.42K
Adams street partners---298.99K
Perceptive advisors---266.29K
Nantahala capital management---250.06K
Opaleye management---172.36K

New Positions

HolderShares% AssetsChangeValue
Frontier capital management374.04K0.48%374.04K$46.62M
Primecap management co/ca/195.03K0.02%195.03K$24.31M
Alyeska investment group179.92K0.06%179.92K$22.43M
Emerald advisers161.50K0.64%161.50K$20.13M
First turn management148.09K2.06%148.09K$18.46M

Sold Out

HolderChange
Rockefeller capital management-5.00
Physician wealth advisors-8.00
Optima capital-8.00
Sbi securities-12.00
Federation des caisses desjardins du quebec-18.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202618626.53%13,145,25834.69%1161.50%12930.30%30-
Dec 31, 202590-11.76%4,478,390-47.47%400.68%61-8.96%15-21.05%
Sep 30, 202552-16.13%2,330,158-59.04%210.80%33-19.51%1122.22%
Jun 30, 20256562.50%5,909,71115.35%532.47%4491.30%9125.00%
Mar 31, 20254021.21%5,124,16727.05%2300.70%2471.43%4-33.33%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv361.69K2.53%-
State Street® SPDR® S&P® Biotech ETF303.03K2.12%-2.18K
Federated Hermes Kaufmann Growth276.56K1.93%43.60K
Federated Hermes Kaufmann R276.56K1.93%43.60K
MEDICAL BioHealth EUR Acc189.27K1.32%117.00
PGIM Jennison Health Sciences Z183.04K1.28%-
Jennison Health Sciences Equity183.04K1.28%21.78K
iShares Russell 2000 ETF181.99K1.27%1.55K
PRIMECAP Odyssey Aggressive Growth163.47K1.14%163.47K
Federated Hermes Kaufmann Small Cap A150.50K1.05%20.43K

Recent Insider Transactions

DateNameRoleActivityValue
May 20, 2026Goin Kathleen Chief Operating OfficerSell$5.37K
May 20, 2026Goin Kathleen Chief Operating OfficerSell$99.17K
May 20, 2026Goin Kathleen Chief Operating OfficerSell$371.09K
Apr 15, 2026Goin Kathleen Chief Operating OfficerSell$71.94K
Apr 15, 2026Goin Kathleen Chief Operating OfficerSell$189.20K

Insider Transactions Trends

DateBuySell
2026 Q2-8
2026 Q137
2025 Q4-3
2025 Q22-
2025 Q1--

PVLA Ownership FAQ

Who Owns Palvella Therapeutics?

Palvella Therapeutics shareholders are primarily institutional investors at 116.83%, followed by 11.65% insiders and -28.48% retail investors. The average institutional ownership in Palvella Therapeutics's industry, Biotech Stocks , is 35.75%, which Palvella Therapeutics exceeds.

Who owns the most shares of Palvella Therapeutics?

Palvella Therapeutics’s largest shareholders are Suvretta capital management (1.15M shares, 10.25%), First light asset management (980.76K shares, 8.72%), and Bvf inc/il (960.99K shares, 8.54%). Together, they hold 27.51% of Palvella Therapeutics’s total shares outstanding.

Does Blackrock own Palvella Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Palvella Therapeutics.

Who is Palvella Therapeutics’s biggest shareholder by percentage of total assets invested?

First light asset management is Palvella Therapeutics’s biggest shareholder by percentage of total assets invested, with 10.96% of its assets in 980.76K Palvella Therapeutics shares, valued at 122.25M$.

Who is the top mutual fund holder of Palvella Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Palvella Therapeutics shares, with 2.53% of its total shares outstanding invested in 361.69K Palvella Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools